Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) InitiativeOfir Wolach, Aaron D. Goldberg, Jacqueline S. Garcia et al.|Blood|2022Cited by 2
Impact Of Race on Baseline Asthma Severity and Response to Biologic Therapy in the First 12 Months Post Biologic InitiationMonica Littlejohn, Natalia Petruski‐Ivleva, Nicolas Gargurevich et al.|Journal of Allergy and Clinical Immunology|2025Cited by 0